Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (NYSE: ABT) announced it will release its fourth-quarter 2024 financial results on Wednesday, January 22, before market open. The company will host a live webcast earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern). Investors can access the webcast through Abbott's Investor Relations website at www.abbottinvestor.com. An archived version of the call will be made available later the same day.
Abbott (NYSE: ABT) has achieved a significant milestone by completing the world's first leadless left bundle branch area pacing (LBBAP) procedures using their investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system. The procedures were conducted as part of a feasibility study evaluating the system's acute safety and performance.
The innovative device, which has received FDA Breakthrough Device Designation, is designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system. This approach combines the benefits of both conduction system pacing and leadless pacing technologies, potentially offering improved physiological response compared to traditional pacing options.
The procedures were performed by Prof. Petr Neužil at Na Homolce Hospital in Prague and Dr. Vivek Y. Reddy from Mount Sinai Hospital in fall 2024.
Abbott (NYSE: ABT) has announced a 7.3% increase in its quarterly common dividend to 59 cents per share, marking its 53rd consecutive year of dividend growth. The company's quarterly dividend payout has grown more than 60% since 2020, demonstrating consistent shareholder value creation. This will be Abbott's 404th consecutive quarterly dividend since 1924. The dividend is payable on February 14, 2025, to shareholders of record as of January 15, 2025. Abbott maintains its position in the S&P 500 Dividend Aristocrats Index, which includes companies with at least 25 consecutive years of dividend increases.
Abbott and the Big Ten Conference's 'We Give Blood Drive' competition saw nearly 20,000 participants donate blood across the country, potentially saving up to 60,000 lives. The University of Nebraska-Lincoln won the competition, receiving a $1 million grant from Abbott to advance student and community health.
The initiative aimed to address one of the biggest blood shortages in a generation, particularly noting the decline in donors aged 19-24 by nearly a third in recent years. More than half of the campus blood drive donors were first-time contributors. The competition ran from September 26 through December 6 and will return next football season.
Abbott (NYSE: ABT) announced its first patient procedures using an investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating severe aortic stenosis. This system represents the initial phase toward developing a software-guided TAVI system with AI capabilities. The technology will complement Abbott's existing Navitor™ TAVI system, offering physicians additional options for patient treatment.
The balloon-expandable device works by crimping a new heart valve on a deflated balloon, which is inserted through a leg artery and guided to the heart. The balloon is then inflated to expand the valve, replacing the function of the narrowed native valve.
Tidepool announces a new cloud-to-cloud data integration partnership with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. This integration will enable automatic data streaming from Abbott's CGMs to Tidepool+, a diabetes data visualization and population health platform. The collaboration aims to streamline diabetes care workflows and expand patient choice.
The integration will allow clinics and health systems using Tidepool+ to establish connections with patients using FreeStyle Libre 2 and 3 systems, either in-clinic or remotely. The platform will merge data from FreeStyle Libre sensors into its Population Health Dashboard, providing clinicians with comprehensive patient outcome assessments.
Tidepool announces a new cloud-to-cloud data integration with Abbott's FreeStyle Libre portfolio of continuous glucose monitoring (CGM) systems in the U.S. The integration will enable automatic data streaming from FreeStyle Libre 2 and 3 systems to Tidepool+, a diabetes data visualization and population health platform. This collaboration aims to streamline diabetes care workflows and provide better access to device data through interoperable solutions. Healthcare providers will be able to initiate connections with patients either in clinic or remotely, creating a comprehensive overview of patient outcomes through the Population Health Dashboard.
Tidepool has announced a new cloud-to-cloud data integration partnership with Abbott (NYSE: ABT) for continuous glucose monitoring (CGM). The integration will enable automatic data streaming from Abbott's FreeStyle Libre CGM devices to Tidepool+, a diabetes data visualization and population health platform. This partnership allows healthcare providers to initiate connections with patients using FreeStyle Libre 1, 2, and 3 devices, both in-clinic and remotely. The integration aims to streamline diabetes care workflows and provide comprehensive patient data overview through Tidepool's Population Health Dashboard.
Abbott (NYSE: ABT) announced the launch of TEAM-HF, a groundbreaking clinical trial aimed at improving outcomes for advanced heart failure patients. The study will enroll up to 850 patients across 75 sites worldwide, using Abbott's CardioMEMS™ HF System to monitor pulmonary artery pressures and identify patients who could benefit from early HeartMate 3™ left ventricular assist device intervention. The trial addresses a critical gap in heart failure treatment, as approximately 6.7 million Americans have heart failure, with numbers expected to reach 8.5 million by 2030. The study's primary and secondary endpoints will be evaluated at two years, with follow-up through five years.
Abbott (NYSE:ABT) and the Big Ten Conference have launched 'The We Give Blood Drive,' a first-ever conference-wide blood donation competition. Running from Sept. 26 through Dec. 6, the initiative aims to address critical U.S. blood shortages by engaging 18 member schools' students, alumni, and fans. The school generating the most donations will receive a $1 million grant for student or community health, announced at the Big Ten Championship Game on Dec. 7. Participants receive a free one-month B1G+ streaming subscription and entry to win championship game tickets. The competition addresses declining younger donor numbers and aims to ensure a stable blood supply.